**Supplementary Table 1.** Treatment Outcomes in Patients with Eyelid Myoclonia with Absences

| Patient | Medications Tried | Remission at the last follow-up | Current Effective Therapy | Previously Effective Therapy1 |
| --- | --- | --- | --- | --- |
| 1. | CBZ; VPA | yes | VPA | none |
| 2. | LEV; LTG; VPA | yes | VPA | none |
| 3. | LTG; VPA LEV + LTG | yes | LTG | LEV + LTGVPA |
| 4. | ETX + LTG; VPA | yes | ETX + LTG | VPA |
| 5. | LTG; ETX; VPA | no | none | none |

1 — remission for at least 12 months.

CBZ — Carbamazepine; ETX ­— Ethosuximide; VPA ­­— Valproic Acid; LEV — Levetiracetam; LTG ­— Lamotrigine

**Supplementary Table 2**. Treatment regimens at the last follow up-visit

|  |  |
| --- | --- |
| **Monotherapy at the last follow up; n (%)**   LEV   VPA   LTG   CBZ   OXC   ETX   PB | 105 (81.5)42 (32.3)32 (24.6)24 (18.5)3 (2.3)2 (1.5)1 (0.8)1 (0.8) |
| **Polytherapy at the last follow up; n (%)** **2 ASMs**         ETX + LTG         ETX + VPA         LEV + LTG         LEV + VPA         LTG + TPM         LTG + VPA         VPA + TPM   **≥ 3 ASMs**CLZ+LEV+VPA         LEV+VPA+TPM | 23 (17.7)**21 (16.2)** 1 (0.8) 1 (0.8) 9 (6.9) 3 (2.3) 1 (0.8) 4 (3.1) 2 (1.5) **2 (1.5)** 1 (0.8) 1 (0.8) |

ASMs — antiseizure medications; CBZ ­— Carbamazepine; CLZ — Clonazepam; ETX —Ethosuximide; LEV — Levetiracetam; LTG — Lamotrigine; OXC — Oxcarbazepine; PB — Phenobarbital; TPM ­— Topiramate; VPA — Valproate

**Supplementary Figure 1.** Comparison of seizure-free rates in patients using valproate versus lamotrigine/levetiracetam/lamotrigine + levetiracetam



LEV — Levetiracetam; LTG — Lamotrigine; VPA — Valproate

**Supplementary Figure 2.** Seizure outcome at last medical observation according to different
IGE syndrome



JME — juvenile myoclonic epilepsy; GTCA — epilepsy with generalized tonic-clonic seizures alone; JAE ­— juvenile absence epilepsy; CAE — childhood absence epilepsy